Меню
Идёт набор NCT07047573

Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

— Наблюдательное Lung Cancer (Diagnosis) Pulmonary Nodule Persistent

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer.
Кому может быть актуально
Состояния в реестре: Lung Cancer (Diagnosis), Pulmonary Nodule Persistent. Базовые параметры: Без ограничений · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Clinical Application Research on Differentiating Benign and Malignant Pulmonary Nodules Based on Multi-omics Detection Technology

Обзор

Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer

Подробное описание

Research design: It is planned to collect pulmonary nodules confirmed by preoperative CT during the period from January 2021 to June 2020 The peripheral blood and clinical information of 100 patients who underwent surgical operations were classified according to the pathological diagnosis of the patients It is the malignant pulmonary nodule group and the benign pulmonary nodule group. Through single-cell sequencing, flow cytometry analysis and radiomics The purpose of identifying the benign and malignant nature of pulmonary nodules is: ① To predict the benign and malignant nature of pulmonary nodules before surgery; ② Explore evil the differences in the immune microenvironment between patients with sexual and benign pulmonary nodules, and the search for specific markers with clinical value Object ③ Compare the diagnostic sensitivity of the new prediction method with that of traditional tumor markers and explore its role as a predictor The potential for measuring the benign and malignant nature of pulmonary nodules

Вмешательства

  • Биопрепарат PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer
    Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is

Первичные конечные точки

  • Changes in peripheral blood immune indicators, differences in radiomics and clinicopathological characteristics [Срок оценки: Before surgery for patients with pulmonary nodules]
  • Tumor antigen-specific T cells were detected by flow cytometry or single-cell sequencing to determine the differences in the immune microenvironment between patients with benign pulmonary nodules and those with malignant pulmonary nodules. [Срок оценки: Before surgery for patients with pulmonary nodules]

Критерии участия

Критерии включения

  • Patient underwent a ct examination
  • Patient was confirmed to have pulmonary nodules
  • Patient has been determined to undergo surgical treatment
  • There are clear pathological results
  • The clinicopathological data are complete

Критерии исключения

  • Patient has no ct examination results
  • Refuse surgical treatment
  • Patient has no clear pathological diagnosis
  • Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
  • Patients with tumor emergencies that require immediate treatment.
  • Poor vascular conditions.
  • Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
  • Patients with hematogenic infectious diseases, such as HBV.
  • Patients with psychiatric disorders or severe mental illnesses.
  • Patients who have difficulty communicating or are unable to be followed up for a long time

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Случай-контроль

Центры проведения

Китай · 1 центр
  • Soochow university — Сучжоу

Идентификаторы

NCT: NCT07047573 · 2024735

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗